| Oct 4 |
Kezar zetomipzomib IND for lupus placed on FDA clinical hold
|
| Oct 4 |
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
|
| Oct 1 |
Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug
|
| Sep 30 |
Kezar Life Sciences Suspends Enrollment, Dosing in Phase 2b Trial of Zetomipzomib in Active Lupus Nephritis Patients
|
| Sep 30 |
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
|
| Sep 4 |
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 14 |
Kezar stalls solid tumour trial to focus on autoimmune disease candidate
|
| Aug 13 |
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| May 29 |
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
|
